After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...